125 related articles for article (PubMed ID: 25098985)
21. Podoplanin expression as a predictive marker of dysplasia in oral leukoplakia.
Gissi DB; Gabusi A; Tarsitano A; Luccarini L; Morandi L; Montebugnoli L
J Craniomaxillofac Surg; 2018 May; 46(5):759-764. PubMed ID: 29588189
[TBL] [Abstract][Full Text] [Related]
22. Association of podoplanin expression to histopathological grades of oral epithelial dysplasia and oral squamous cell carcinoma.
Shabir H; Durrani SH; Tariq SF; Khatak SS; Khan AS; Arbab KN
J Pak Med Assoc; 2024 May; 74(5):852-856. PubMed ID: 38783429
[TBL] [Abstract][Full Text] [Related]
23. A Comparison of Podoplanin Expression in Oral Leukoplakia and Oral Squamous Cell Carcinoma: An Immunohistochemical Study.
Srinivasan V; Shyam N; Kumar GK; Narayen V; Konda P; Swetha Rani K
Cureus; 2023 May; 15(5):e38467. PubMed ID: 37273383
[TBL] [Abstract][Full Text] [Related]
24. Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy.
Kreppel M; Drebber U; Wedemeyer I; Eich HT; Backhaus T; Zöller JE; Scheer M
Oral Oncol; 2011 Sep; 47(9):873-8. PubMed ID: 21767977
[TBL] [Abstract][Full Text] [Related]
25. Dual role of podoplanin in oral cancer development.
Cîrligeriu L; Cimpean AM; Raica M; Doroş CI
In Vivo; 2014; 28(3):341-7. PubMed ID: 24815836
[TBL] [Abstract][Full Text] [Related]
26. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression.
Mishra R; Das BR
Arch Oral Biol; 2009 Oct; 54(10):917-23. PubMed ID: 19679297
[TBL] [Abstract][Full Text] [Related]
27. Osteopontin: a marker for invasive oral squamous cell carcinoma but not for potentially malignant epithelial dysplasias.
Routray S; Kheur SM; Kheur M
Ann Diagn Pathol; 2013 Oct; 17(5):421-4. PubMed ID: 23711950
[TBL] [Abstract][Full Text] [Related]
28. Expression of inducible nitric oxide synthase (iNOS) in oral precancer and oral squamous cell carcinoma: an immunohistochemical study.
Varghese SS; Sunil PM; Madhavan RN
Cancer Biomark; 2010-2011; 8(3):155-60. PubMed ID: 22012771
[TBL] [Abstract][Full Text] [Related]
29. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis.
Arora S; Kaur J; Sharma C; Mathur M; Bahadur S; Shukla NK; Deo SV; Ralhan R
Clin Cancer Res; 2005 Mar; 11(6):2272-84. PubMed ID: 15788677
[TBL] [Abstract][Full Text] [Related]
30. Metallothionein and p-Akt proteins in oral dysplasia and in oral squamous cell carcinoma: an immunohistochemical study.
Pontes HA; de Aquino Xavier FC; da Silva TS; Fonseca FP; Paiva HB; Pontes FS; dos Santos Pinto D
J Oral Pathol Med; 2009 Sep; 38(8):644-50. PubMed ID: 19453843
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia.
Schaaij-Visser TB; Bremmer JF; Braakhuis BJ; Heck AJ; Slijper M; van der Waal I; Brakenhoff RH
Oral Oncol; 2010 Feb; 46(2):123-7. PubMed ID: 20036603
[TBL] [Abstract][Full Text] [Related]
32. Podoplanin--a novel marker in oral carcinogenesis.
Swain N; Kumar SV; Routray S; Pathak J; Patel S
Tumour Biol; 2014 Sep; 35(9):8407-13. PubMed ID: 24964963
[TBL] [Abstract][Full Text] [Related]
33. The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia.
Ries J; Vairaktaris E; Agaimy A; Bechtold M; Gorecki P; Neukam FW; Nkenke E
Oncol Rep; 2013 Sep; 30(3):1149-56. PubMed ID: 23784518
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast Growth Factor (FGF-2) and Its Receptors FGFR-2 and FGFR-3 May Be Putative Biomarkers of Malignant Transformation of Potentially Malignant Oral Lesions into Oral Squamous Cell Carcinoma.
Nayak S; Goel MM; Makker A; Bhatia V; Chandra S; Kumar S; Agarwal SP
PLoS One; 2015; 10(10):e0138801. PubMed ID: 26465941
[TBL] [Abstract][Full Text] [Related]
35. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.
Kaur J; Matta A; Kak I; Srivastava G; Assi J; Leong I; Witterick I; Colgan TJ; Macmillan C; Siu KW; Walfish PG; Ralhan R
Int J Cancer; 2014 Mar; 134(6):1379-88. PubMed ID: 24122701
[TBL] [Abstract][Full Text] [Related]
36. Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas.
Rodrigo JP; García-Carracedo D; González MV; Mancebo G; Fresno MF; García-Pedrero J
Mol Cancer; 2010 Mar; 9():48. PubMed ID: 20196862
[TBL] [Abstract][Full Text] [Related]
37. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
Retzbach EP; Sheehan SA; Nevel EM; Batra A; Phi T; Nguyen ATP; Kato Y; Baredes S; Fatahzadeh M; Shienbaum AJ; Goldberg GS
Oral Oncol; 2018 Mar; 78():126-136. PubMed ID: 29496040
[TBL] [Abstract][Full Text] [Related]
38. Phospholipase C-γ1 expression correlated with cancer progression of potentially malignant oral lesions.
Ma LW; Zhou ZT; He QB; Jiang WW
J Oral Pathol Med; 2013 Jan; 42(1):47-52. PubMed ID: 22671975
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of SOX2 and podoplanin expression in oral epithelial dysplasia and its correlation with malignant transformation.
Verma V; Chandrashekar C
J Investig Clin Dent; 2019 Nov; 10(4):e12450. PubMed ID: 31464104
[TBL] [Abstract][Full Text] [Related]
40. Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Ohta M; Abe A; Ohno F; Hasegawa Y; Tanaka H; Maseki S; Kondo E; Kurita K; Nakanishi H
Oral Oncol; 2013 Jan; 49(1):20-6. PubMed ID: 22840788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
